Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top

Targeted Oncology

Issue 1/2011

Content (6 Articles)

Editorial

Targeting the target of rapamycin (TOR): looking to mother nature

Eric K. Rowinsky

Review

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

Sumanta Kumar Pal, Robert A. Figlin

Review

Mechanisms of mTOR inhibitor resistance in cancer therapy

Jennifer S. Carew, Kevin R. Kelly, Steffan T. Nawrocki

Review

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

Sushma Vemulapalli, Alain Mita, Yesid Alvarado, Kamalesh Sankhala, Monica Mita

Review

Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Zelton Dave Sharp, Arlan Richardson

Review

Mammalian target of rapamycin as a target in hematological malignancies

Kevin R. Kelly, Julie H. Rowe, Swaminathan Padmanabhan, Steffan T. Nawrocki, Jennifer S. Carew

Dec 10
Issue: 4/2010
Jun 11
Issue: 2/2011

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits